real-world outcomes of teclistamab for r/r multiple myeloma
Published 5 months ago • 79 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
0:56
real-world survival in patients with mixed phenotype attr-cm treated with tafamidis
-
1:06
fedratinib: mpn-associated myelofibrosis
-
4:11
impact of ruxolitinib approval on myelofibrosis real-world survival in the us
-
2:14
improved survival of myelofibrosis patients receiving ruxolitinib post allo-hsct
-
0:45
difference between quality of life & patient-reported outcomes
-
1:55
piccolo xpress with capillary tube
-
3:40
pros and cons of ruxolitinib for the treatment of mpns
-
6:54
mis reports
-
1:20
to jaki or not to jaki - treating early mf
-
2:22
real-world outcomes following dose reduction of first-line ibrutinib in patients with wm
-
2:47
real-world data on the safety of emicizumab in patients with hemophilia a
-
1:19
fedratibib improves hrqol in myelofribrosis
-
6:31
the importance of patient perspectives and real-world data
-
5:24
krt‑232: first-in-class mdm2i for myelofibrosis r/r to jak inhibitor therapy
-
2:00
real-world bortezomib prescribing patterns and outcomes in ndmm
-
2:54
the influence of ibrutinib on progression-free survival and complete survival
-
2:53
real-world data on upfront subcutaneous bortezomib-containing regimens for newly diagnosed myeloma
-
2:43
collecting real world data from novel treatments
-
3:48
real world evidence: what is it and what can it tell us?
-
52:15
sources of real world data: patient reported outcomes collected during routine health care delivery
-
0:42
the importance of obtaining real-world data
-
6:31
report filling